
24/09/2025
BEYOND NADINA – THE NEW WAVE OF NEOADJUVANT CLINICAL TRIALS
MIA Medical Director, Prof Georgina Long AO, is leading the next group of clinical trials in the use of pre-surgery immunotherapy as life-saving treatment for melanoma.
Professor Long said although the NADINA clinical trial was practice-changing globally, thanks to the collaborative efforts of trial teams around the world, there was still much more to do.
‘The breakthrough NADINA trial laid the groundwork for this next series of neoadjuvant, or pre-surgery, immunotherapy clinical trials,’
‘Our focus is now on deep translational work to test different combinations of neoadjuvant immunotherapy to try to achieve even better response and progression-free survival rates,’
Results of one of these latest neoadjuvant immunotherapy clinical trials were today published in the prestigious Nature Medicine. Professor Long co-designed the Morpheus-Melanoma trial with the team at Roche, which was a global randomized umbrella study conducted at 14 centres across Australia, France, Italy, Spain and the United States.
Read more > https://bit.ly/4pDDg8V